Skip to main content
SpringerLink
Log in

The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues

  • Rapid Communication
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Acromegaly is known to be associated to vascular damage characterized by an increase of vascular wall thickness and an impairment of vascular function. Aim: The aim of this study was to evaluate the effect of medical treatment with the GH receptor antagonist pegvisomant on vascular structure and function in acromegalic patients resistant to somatostatin analogues. Patients: Ten patients (4 males and 6 females, 28–58 yr) and 20 sex-, age-, and body mass index-matched healthy controls entered the study. All patients were treated for 18 months with pegvisomant at doses ranging from 10 to 40 mg/day. Outcome measures: Primary outcome measures were measurement of carotid arteries intima-media thickness (IMT), and brachial arteries flow mediated dilation (FMD); secondary outcome measures were blood pressure, blood glucose and lipids levels. Results: Carotid arteries maximal IMT was significantly higher in patients than in controls at baseline (1.18±0.59 vs 0.69±0.13, p=0.001) and slightly, but not significantly, decreased after treatment (0.97±0.17). Brachial arteries FMD was significantly lower in patients than controls at baseline (7.5±2.5 vs 13.1±1.4, p<0.001) and significantly increased after treatment (8.8±3.7, p=0.016). Systolic (SBP) and diastolic (DBP) blood pressure values, serum glucose and insulin levels and homeostasis model assessment (HOMA) index were higher, whereas HDL-cholesterol levels were lower in patients than controls at baseline. After treatment, SBP and DBP, as well as serum glucose and insulin levels and HOMA index significantly decreased whereas no significant change was found in serum lipid profile. Conclusions: The results of the current study suggested that long-term treatment with pegvisomant induced a slight reduction of carotid arteries wall thickness and a significant improvement of brachial arteries vascular function in patients with acromegaly resistant to somatostatin analogues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25:102–52.

    Article  PubMed  CAS  Google Scholar 

  2. Wright AD, Hill DM, Lowy C, Fraser TR. (1970) Mortality in acromegaly. QJ Med 1970, 39: 1–16.

    CAS  Google Scholar 

  3. Colao A, Spiezia S, Cerbone G, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 2001, 54: 515–24.

    Article  CAS  Google Scholar 

  4. Otsuki M, Kasayama S, Yamamoto H, et al. (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 2001, 54: 791–6.

    Article  CAS  Google Scholar 

  5. Chanson P, Megnien JL, del Pino M, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol (Oxf) 1998, 49: 725–31.

    Article  CAS  Google Scholar 

  6. Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab 2002, 87: 3174–9.

    Article  PubMed  CAS  Google Scholar 

  7. Schiavon F, Maffei P, Martini C, et al. Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab 1999, 84: 3151–5.

    PubMed  CAS  Google Scholar 

  8. Maison P, Démolis P, Young J, Schaison G, Giudicelli JF, Chanson P. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 2000, 53: 445–51.

    Article  CAS  Google Scholar 

  9. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003, 58: 169–76.

    Article  CAS  Google Scholar 

  10. Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002, 146: 303–9.

    Article  PubMed  CAS  Google Scholar 

  11. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006, 154: 467–77.

    Article  PubMed  CAS  Google Scholar 

  12. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf) 2002, 56: 303–11.

    Article  CAS  Google Scholar 

  13. Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 2007, 92: 476–82.

    Article  PubMed  CAS  Google Scholar 

  14. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002, 87: 1692–9.

    Article  PubMed  CAS  Google Scholar 

  15. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342: 1171–7.

    Article  PubMed  CAS  Google Scholar 

  16. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358: 1754–9.

    Article  PubMed  Google Scholar 

  17. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526–9.

    PubMed  CAS  Google Scholar 

  18. Dilley RJ, Schwartz SM. Vascular remodeling in the growth hormone transgenic mouse. Circ Res 1989, 65: 1233–40.

    Article  PubMed  CAS  Google Scholar 

  19. Andersson IJ, Johansson ME, Wickman A, et al. Endothelial dysfunction in growth hormone transgenic mice. Clin Sci (Lond) 2006, 110: 217–25.

    Article  CAS  Google Scholar 

  20. Bohlooly YM, Carlson L, Olsson B, et al. Vascular function and blood pressure in GH transgenic mice. Endocrinology 2001, 142: 3317–23.

    Article  Google Scholar 

  21. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993, 6: 260S–70S.

    Article  PubMed  CAS  Google Scholar 

  22. Cohen R, Chanson P, Bruckert E, et al. Effects of octreotide on lipid metabolism in acromegaly. Horm Metab Res 1992, 24: 397–400.

    Article  PubMed  CAS  Google Scholar 

  23. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992, 36: 271–9.

    Article  CAS  Google Scholar 

  24. Moller N, Schmitz O, Jøorgensen JO, et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992, 74:1012–9.

    PubMed  CAS  Google Scholar 

  25. Oscarsson J, Wiklund O, Jakobsson KE, Petruson B, Bengtsson BA. Serum lipoproteins in acromegaly before and 6–15 months after transsphenoidal adenomectomy. Clin Endocrinol (Oxf) 1994, 41: 603–8.

    Article  CAS  Google Scholar 

  26. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005, 90: 5684–91.

    Article  PubMed  CAS  Google Scholar 

  27. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005, 90: 5627–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular & Clinical Endocrinology and Oncology, “Federico II” University of Naples, via S. Pansini 5, 80131, Naples

    M. C. De Martino, R. S. Auriemma, M. Galdiero, L. Grasso, G. Lombardi, A. Colao & R. Pivonello MD, PhD

  2. Department of Internal Medicine, Division of Cardiovascular and Immunological Sciences, Federico II University, Naples

    G. Brevetti & V. Schiano

  3. Department of Endocrinology, San Luca Hospital, Italian Auxological Institute, University of Milan, Milan, Italy

    G. Vitale

Authors
  1. M. C. De Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. S. Auriemma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Brevetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Schiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Galdiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Grasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Pivonello MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Pivonello MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Martino, M.C., Auriemma, R.S., Brevetti, G. et al. The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 33, 663–670 (2010). https://doi.org/10.1007/BF03346667

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346667

Key-words

Search

Navigation